AP2870A - Odcase inhibitors for the treatment of malaria - Google Patents

Odcase inhibitors for the treatment of malaria

Info

Publication number: AP2870A
Authority: AP; ARIPO
Prior art keywords: odcase; malaria; inhibitors; treatment; odcase inhibitors
Prior art date: 2005-10-03

Application number

AP2008004436A

Other languages

English (en)

Other versions

AP2008004436A0 (en

Inventor

Angelica Bello

Masahiro Fujihashi

Lakshmi P Kotra

Original Assignee

Univ Health Network

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-10-03

Filing date

2006-10-03

Publication date

2014-03-31

2006-10-03 Application filed by Univ Health Network filed Critical Univ Health Network

2008-04-30 Publication of AP2008004436A0 publication Critical patent/AP2008004436A0/xx

2014-03-31 Application granted granted Critical

2014-03-31 Publication of AP2870A publication Critical patent/AP2870A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/073—Pyrimidine radicals with 2-deoxyribosyl as the saccharide radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/067—Pyrimidine radicals with ribosyl as the saccharide radical
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Virology (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Tropical Medicine & Parasitology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Genetics & Genomics (AREA)
Pulmonology (AREA)
AIDS & HIV (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

AP2008004436A 2005-10-03 2006-10-03 Odcase inhibitors for the treatment of malaria AP2870A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US59653705P	2005-10-03	2005-10-03
US59714205P	2005-11-12	2005-11-12
PCT/CA2006/001620 WO2007038859A1 (fr)	2005-10-03	2006-10-03	Inhibiteurs d'odcase pour le traitement du paludisme

Publications (2)

Publication Number	Publication Date
AP2008004436A0 AP2008004436A0 (en)	2008-04-30
AP2870A true AP2870A (en)	2014-03-31

Family

ID=37905934

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2008004436A AP2870A (en)	2005-10-03	2006-10-03	Odcase inhibitors for the treatment of malaria

Country Status (7)

Country	Link
US (2)	US20100087388A1 (fr)
EP (1)	EP1931691B1 (fr)
CN (1)	CN101321775B (fr)
AP (1)	AP2870A (fr)
CA (1)	CA2665370A1 (fr)
ES (1)	ES2436404T3 (fr)
WO (2)	WO2007038860A2 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008083465A1 (fr) *	2007-01-08	2008-07-17	University Health Network	Dérivés de pyrimidine comme agents anti-cancer
HUE025528T2 (en)	2008-04-23	2016-05-30	Gilead Sciences Inc	1'-substituted carba-nucleoside analogs for antiviral treatment
KR20110112844A (ko)	2009-01-26	2011-10-13	한국화학연구원	Ｈｉｖ 역전사효소 억제제의 제조 방법
ME01528B (me)	2009-09-21	2014-04-20	Gilead Sciences Inc	POSTUPCI l INTERMEDIJERI ZA PROIZVODNJU 1'-CIJANOKARBANUKLEOZIDIH ANALOGA
EP2805960A1 (fr)	2010-07-19	2014-11-26	Gilead Sciences, Inc.	Procédés pour la préparation de promédicaments de phosphoramidate pur diastéromérique
US20120027752A1 (en)	2010-07-22	2012-02-02	Gilead Sciences, Inc.	Methods and compounds for treating paramyxoviridae virus infections
CA2812962C (fr)	2010-09-22	2020-03-31	Alios Biopharma, Inc.	Azido nucleosides et analogues nucleotidiques
MX356509B (es)	2011-12-22	2018-05-30	Alios Biopharma Inc	Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
USRE48171E1 (en)	2012-03-21	2020-08-25	Janssen Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
US9441007B2 (en)	2012-03-21	2016-09-13	Alios Biopharma, Inc.	Substituted nucleosides, nucleotides and analogs thereof
CA2890359A1 (fr) *	2012-11-07	2014-05-15	Zucai SUO	Analogues arylamides substitues de gemcitabine
TWI767201B (zh)	2014-10-29	2022-06-11	美商基利科學股份有限公司	絲狀病毒科病毒感染之治療
HRP20220355T1 (hr)	2015-09-16	2022-05-13	Gilead Sciences, Inc.	Postupci za liječenje infekcija coronaviridae
US11617753B2 (en) *	2016-11-10	2023-04-04	Oyagen, Inc.	Methods of treating and inhibiting Ebola virus infection
TW201836615A (zh)	2017-03-14	2018-10-16	美商基利科學股份有限公司	治療貓冠狀病毒感染之方法
CA3059777C (fr)	2017-05-01	2023-02-21	Gilead Sciences, Inc.	Formes cristallines de (s) 2 ethylbutyl 2 (((s) (((2r,3s,4r,5r) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazine-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphor yl)amino)propanoate
WO2018232174A2 (fr) *	2017-06-16	2018-12-20	Avalon Flaviviral Therapeutics (Hk) Limited	Compositions et procédé pour le traitement d'infections de flavivirus
WO2019014247A1 (fr)	2017-07-11	2019-01-17	Gilead Sciences, Inc.	Compositions comprenant un inhibiteur d'arn polymérase et de la cyclodextrine pour le traitement d'infections virales
US10435429B2 (en)	2017-10-03	2019-10-08	Nucorion Pharmaceuticals, Inc.	5-fluorouridine monophosphate cyclic triester compounds
WO2019139920A1 (fr)	2018-01-10	2019-07-18	Nucorion Pharmaceuticals, Inc.	Composés de phosphore(n)amidatacétal et phosph(on)atalcétal
US11427550B2 (en)	2018-01-19	2022-08-30	Nucorion Pharmaceuticals, Inc.	5-fluorouracil compounds
AU2020315394A1 (en)	2019-07-17	2022-02-17	Nucorion Pharmaceuticals, Inc.	Cyclic deoxyribonucleotide compounds
CN118766947A (zh)	2020-01-27	2024-10-15	吉利德科学公司	用于治疗SARS CoV-2感染的方法
US11738025B2 (en)	2020-02-04	2023-08-29	Oyagen, Inc.	Method for treating coronavirus infections
TWI785528B (zh)	2020-03-12	2022-12-01	美商基利科學股份有限公司	1’-氰基核苷之製備方法
KR20220164784A (ko)	2020-04-06	2022-12-13	길리애드 사이언시즈, 인코포레이티드	1'-시아노 치환된 카르바뉴클레오시드 유사체의 흡입 제형
CN115605492B (zh)	2020-04-21	2025-09-16	配体制药股份有限公司	核苷酸前药化合物
AU2021281351A1 (en)	2020-05-29	2023-01-19	Gilead Sciences, Inc.	Remdesivir treatment methods
PH12022553530A1 (en)	2020-06-24	2024-06-24	Gilead Sciences Inc	1'-cyano nucleoside analogs and uses thereof
ES2985995T3 (es)	2020-08-27	2024-11-08	Gilead Sciences Inc	Compuestos y métodos para el tratamiento de infecciones víricas
US11858956B2 (en)	2020-12-18	2024-01-02	Southern Research Institute	6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
US20230295172A1 (en)	2022-03-02	2023-09-21	Gilead Sciences, Inc.	Compounds and methods for treatment of viral infections
US12357577B1 (en)	2024-02-02	2025-07-15	Gilead Sciences, Inc.	Pharmaceutical formulations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873228A (en) *	1986-09-02	1989-10-10	The University Of Melbourne	2-oxo-4-carboxy-pyrimidines and their use as anti-malaria and anti-cancer agents

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3116282A (en) *	1960-04-27	1963-12-31	Upjohn Co	Pyrimidine nucleosides and process
DD158613A1 (de)	1981-04-20	1983-01-26	Von Janta Lipinski Martin	Verfahren zur herstellung eines virostatischen mittels
CA1223831A (fr)	1982-06-23	1987-07-07	Dean Engelhardt	Nucleotides modifies, methodes de preparation et d'utilisation et composes les contenant
US4872278A (en) *	1988-04-26	1989-10-10	Ross Bruce E	Motion sensitive animated figure display
JPH05140179A (ja)	1991-11-25	1993-06-08	Yamasa Shoyu Co Ltd	９，５′‐シクロヌクレオシド誘導体および該誘導体を製造するための合成中間体
US5646042A (en)	1992-08-26	1997-07-08	Ribozyme Pharmaceuticals, Inc.	C-myb targeted ribozymes
US5891684A (en) *	1992-10-15	1999-04-06	Ribozyme Pharmaceuticals, Inc.	Base-modified enzymatic nucleic acid
US5672501A (en) *	1994-12-23	1997-09-30	Ribozyme Pharmaceuticals, Inc.	Base-modified enzymatic nucleic acid
CA2207593A1 (fr)	1994-12-13	1996-06-20	John Gustofson	Procede et reactif servant a traiter les etats arthritiques, a introduitre une tolerance aux greffes et a inverser les reactions immunes
WO1998050530A2 (fr)	1997-05-09	1998-11-12	Ribozyme Pharmaceuticals, Inc.	Traitement a l'acide nucleique enzymatique de maladies et etats pathologiques associes aux niveaux d'expression de c-raf
DE19801120A1 (de) *	1998-01-15	1999-07-22	Basf Ag	Orotidin-5'-Phosphatdecarboxylase-Gen, Genkonstrukt enthaltend dieses Gen und seine Verwendung
US6130035A (en) *	1998-02-20	2000-10-10	Brusilow Enterprise Llc	Use of orotidine monophosphate decarboxylase inhibition in a method for cancer screening
US6020483A (en) *	1998-09-25	2000-02-01	Nexstar Pharmaceuticals, Inc.	Nucleoside modifications by palladium catalyzed methods
CA2426187C (fr)	2000-10-18	2011-08-16	Pharmasset Limited	Nucleosides modifies pour le traitement des infections virales et de la proliferation cellulaire anormale
AU2002252183A1 (en)	2001-03-06	2002-09-19	Biocryst Pharmaceuticals, Inc.	Nucleosides, preparation thereof and use as inhibitors of rna viral polymerases
DE10159606A1 (de)	2001-12-05	2003-06-12	Basf Ag	Verpackungsmaterial, enthaltend eine Polyurethan-Dispersion
WO2003064621A2 (fr)	2002-02-01	2003-08-07	Ambion, Inc.	Courts fragments d'arn interferant haute activite visant a reduire l'expression de genes cibles
AU2003217863B9 (en) *	2002-02-28	2009-10-29	Biota Scientific Management Pty Ltd	Nucleotide mimics and their prodrugs
MXPA05001298A (es)	2002-08-01	2005-11-04	Pharmasset Inc	Compuestos con el sistema biciclo[4.2.1] nonano para el tratamiento de infecciones por flaviviridae.
WO2005020885A2 (fr)	2003-05-21	2005-03-10	Isis Pharmaceuticals, Inc.	Compositions et methodes pour le traitement du syndrome respiratoire aigu severe (sras)

2006
- 2006-10-03 WO PCT/CA2006/001621 patent/WO2007038860A2/fr not_active Ceased
- 2006-10-03 US US12/089,100 patent/US20100087388A1/en not_active Abandoned
- 2006-10-03 US US12/089,120 patent/US8067391B2/en not_active Expired - Fee Related
- 2006-10-03 CA CA002665370A patent/CA2665370A1/fr not_active Abandoned
- 2006-10-03 ES ES06790781T patent/ES2436404T3/es active Active
- 2006-10-03 CN CN2006800454991A patent/CN101321775B/zh not_active Expired - Fee Related
- 2006-10-03 WO PCT/CA2006/001620 patent/WO2007038859A1/fr not_active Ceased
- 2006-10-03 EP EP06790781.6A patent/EP1931691B1/fr not_active Not-in-force
- 2006-10-03 AP AP2008004436A patent/AP2870A/xx active

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4873228A (en) *	1986-09-02	1989-10-10	The University Of Melbourne	2-oxo-4-carboxy-pyrimidines and their use as anti-malaria and anti-cancer agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CAS Registry Number®, 817818-06-2 REGISTRY, Entered STN: Nov. 16, 1984, CN 5-Fluoro-6-iodo-Uridine. *
GABRIELSEN B. ET AL.: 'In vitro and in vivo antiviral (RNA) evalution of orotidine 5'-monophosphate decarboxylase inhibitors and analogs including 6-azauridine-5'-(ethyl methoxyalaminyl)phosphate (a 5'-monophosphate prodrug)' ANTIVIRAL CHEMISTRY CHEMOTHERAPY vol. 5, no. 4, 1994, pages 209 - 220 *
GERO A.M. ET AL.: 'New Malaria Chemotherapy developed by Utilization of a Unique Parasite Transport System' CURRENT PHARMACEUTICAL DESIGN vol. 9, no. 11, 2003, pages 867 - 877 *
Hawley's Condensed Chemical Dictionary, Twelfth Edition, Revised by Richard J. Lewis, Sr., 1993, pp. 355-842. *

Also Published As

Publication number	Publication date
CN101321775A (zh)	2008-12-10
US8067391B2 (en)	2011-11-29
US20100087388A1 (en)	2010-04-08
ES2436404T3 (es)	2013-12-30
WO2007038860A8 (fr)	2007-12-21
EP1931691A4 (fr)	2012-01-11
EP1931691B1 (fr)	2013-08-21
WO2007038859A1 (fr)	2007-04-12
EP1931691A1 (fr)	2008-06-18
US20090221524A1 (en)	2009-09-03
WO2007038860A2 (fr)	2007-04-12
AP2008004436A0 (en)	2008-04-30
CN101321775B (zh)	2012-05-23
CA2665370A1 (fr)	2007-04-12
WO2007038860A3 (fr)	2007-06-07

Publication	Publication Date	Title
AP2870A (en)	2014-03-31	Odcase inhibitors for the treatment of malaria
ZA200802585B (en)	2009-02-25	Pyridopyrimidinone inhibitors of Pl3Kα
IL190292A0 (en)	2009-09-22	PYRIDOPYRIMIDINONE INHIBITORS OF P13Ka
ZA200705783B (en)	2008-09-25	Amino-imidazolones for the inhibition of ß-secretase
ZA200706345B (en)	2009-08-26	Amino-pyridines as inhibitors of ß-secretase
ZA200707650B (en)	2008-11-26	Azolylacylguanidines as ß-secretase inhibitors
IL208607A0 (en)	2010-12-30	Improved nanobodiestm for the treatment of aggregation-mediated disorders
ZA200608221B (en)	2008-08-27	Thiadlazolidinones as GSK-3 Inhibitors
IL189659A0 (en)	2008-08-07	Ikk inhibitors for the treatment of endometriosis
IL189048A0 (en)	2008-08-07	Gsk-3 inhibitors
IL185757A0 (en)	2008-01-06	Methods of decreasing calcifcation
EP1756092A4 (fr)	2009-12-02	Inhibiteurs novateurs de protéines rho-kinases
DK2392335T3 (en)	2015-06-29	Use of 24-norUDCA
IL190139A0 (en)	2008-08-07	Method for the determination of poloxamers
IL187792A0 (en)	2008-11-03	4-anilino-3-quinolinecarbonitriles for the treatment of cancer
GB0515035D0 (en)	2005-08-31	Treatment of atherosclerotic conditions
GB0516967D0 (en)	2005-09-28	Inhibitors
GB0512459D0 (en)	2005-07-27	Removal of nitrogen compounds
GB0602857D0 (en)	2006-03-22	The treatment of sialorrhoea
SI1940839T1 (sl)	2013-10-30	Piridopirimidin PI3K alfa inhibitorji
TJ20050863A (en)	2007-06-05	The way of narcotism treatment
GB2445888B (en)	2010-01-06	Treatment of hypertension
GB0506443D0 (en)	2005-05-04	Novel inhibitors
GB0518003D0 (en)	2005-10-12	Treatment of hepatatis c
GB0602855D0 (en)	2006-03-22	The Treatment Of Sialorrhoea